Drug

angiotensin I (1-7)

In clinical development

Emerging researchLate-stage development

Also known as Angiotensin (1-7), Angiotensin 1-7, Angiotensin-(1-7).

RxNorm46377UNIIIJ3FUK8MOF

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients

Clinical trial2026-06-01Suspended · ClinicalTrials.gov

Metabolic Effects of Angiotensin-(1-7)

Clinical trial2026-05-22Results expected Q4 2029 · ClinicalTrials.gov

Angiotensin-(1-7) Cardiovascular Effects in Aging

Clinical trial2025-09-19Results expected Q4 2026 · ClinicalTrials.gov

Angiotensin-(1-7) and Energy Expenditure in Human Obesity

Clinical trial2025-09-19Results expected Q4 2026 · ClinicalTrials.gov

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

Clinical trial2025-09-19Results expected Q1 2029 · ClinicalTrials.gov

A Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury (TBI)

Clinical trial2025-07-31Results expected Q3 2027 · ClinicalTrials.gov

Biomarker Study: Heart Failure Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia [Supplement of: IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia]

Clinical trial2023-12-01Primary completion · ClinicalTrials.gov

Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension

Clinical trial2023-12-01Terminated · ClinicalTrials.gov

Angiotensin 1-7 as a Therapy for Pneumonia Caused by Coronavirus 2(SARS-CoV-2)

Clinical trial2023-11-01Primary completion · ClinicalTrials.gov

Cardiovascular Effects of Angiotensin 1-7 in Obesity Hypertension

Clinical trial2023-06-03Terminated · ClinicalTrials.gov

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial

Clinical trial2022-12-30Primary completion · ClinicalTrials.gov

Potential influence of COVID-19/ACE2 on the female reproductive system.

Research2020-06-01Molecular human reproduction

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

angiotensin I (1-7)

Aliases & brands

Angiotensin (1-7)Angiotensin 1-7Angiotensin-(1-7)

RxNorm CUI

46377

UNII

IJ3FUK8MOF

Clinical trials

18 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2021

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 18

Early Phase 17Phase 13Phase 1 / 24Phase 23Phase 2 / 31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial

Unknown statusPH II/IIIErasme University Hospitaln=602023

Recent completions

Trials that read out recently, adding to the completed evidence base.

Randomized Clinical Trial Phase I/II for the Use of Angiotensin-(1-7) in the Treatment of Severe Infection by Sars-CoV-2

CompletedPH I/IIErasme University Hospitaln=1122021

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Potential influence of COVID-19/ACE2 on the female reproductive system.

Molecular human reproduction · 2020 · 233 cites